1391052-76-8Relevant articles and documents
PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
-
Paragraph 0281; 0327, (2021/06/22)
Provided herein are phosphodiesterase 4 (PDE4) inhibitors, e.g., a compound of Formula (I) or (II), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disease, disorder, or condition associated with PDE4 malfunction.
Isolation, synthesis and structure confirmation of the impurity in crude roflumilast product
Lin, Yan,Huang, Peijun,Qi, Haofei,Chen, Ligong,Wang, Donghua
, p. 3111 - 3115 (2013/09/23)
An impurity was isolated from crude synthesized roflumilast and characterized by 1H NMR, 13C NMR, and HR-MS, which confirmed the structure as N-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-3- hydroxybenzamide. To further verify the str